Skip to main content

Dube Eric M's Form 4 filing

Travere Therapeutics, Inc. (TVTX) · filed May 6, 2026

Accession no.
0001763494-26-000006
Filed
May 6, 2026
Trade date
May 4-6, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $988.9K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Dube Eric MCIK 0001763494Director, Officer (CHIEF EXECUTIVE OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 4, 2026Common StockMOption exerciseAcquired+22,500$0.00$0455,386Direct
May 6, 2026Common StockSSaleDisposed−22,500$43.95−$988,875432,886Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 4, 2026Common StockAGrant or awardAcquired+45,000$0.00$045,000Direct
May 4, 2026Common StockMOption exerciseDisposed−22,500$0.00$022,500Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)